These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 400699)

  • 1. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) autologous bone marrow transplantation therapy of refractory cancer: a preliminary report.
    Phillips GL; Fay JW; Herzig GP; NaPombejara C; Wolff SN
    Exp Hematol; 1979; 7 Suppl 5():372-83. PubMed ID: 400699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
    Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations.
    Spitzer G; Dicke KA; Verma DS; Zander A; McCredie KB
    Cancer Treat Rep; 1979 Aug; 63(8):1257-64. PubMed ID: 383292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early pulmonary toxicity after administration of high-dose BCNU.
    Litam JP; Dail DH; Spitzer G; Vellekoop L; Verma DS; Zander AR; Dicke KA
    Cancer Treat Rep; 1981; 65(1-2):39-44. PubMed ID: 6261949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous bone-marrow transplantation: host effects of high-dose BCNU.
    Takvorian T; Parker LM; Hochberg FH; Canellos GP
    J Clin Oncol; 1983 Oct; 1(10):610-20. PubMed ID: 6366127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo.
    Moritz T; Mackay W; Glassner BJ; Williams DA; Samson L
    Cancer Res; 1995 Jun; 55(12):2608-14. PubMed ID: 7780976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of primary radiogenic C57BL mouse cell leukemia/lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy and adjuvant cellular therapy.
    Maruyama Y; Feola JM; Kryscio R
    Jpn J Cancer Res; 1985 Dec; 76(12):1236-43. PubMed ID: 3005211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.
    Neben S; Hellman S; Montgomery M; Ferrara J; Mauch P
    Exp Hematol; 1993 Jan; 21(1):156-62. PubMed ID: 8435103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU.
    Levin VA; Stearns J; Byrd A; Finn A; Weinkam RJ
    J Pharmacol Exp Ther; 1979 Jan; 208(1):1-6. PubMed ID: 759602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine DNA methyltransferase complementary DNA.
    Maze R; Kapur R; Kelley MR; Hansen WK; Oh SY; Williams DA
    J Immunol; 1997 Jan; 158(2):1006-13. PubMed ID: 8993023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Fluorouracil, 1,3-bis(2-chloroethyl)-1-nitrosourea, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea: effect on the human granulopoietic system.
    Lohrmann HP; Lepp KA; Schreml W
    J Natl Cancer Inst; 1982 Apr; 68(4):541-7. PubMed ID: 6951071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study.
    Negrier S; Ranchere JY; Philip I; Merrouche Y; Biron P; Blaise D; Attal M; Rebattu P; Clavel M; Pourreau C
    Bone Marrow Transplant; 1991 Oct; 8(4):259-64. PubMed ID: 1756323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.
    Mulder PO; Sleijfer DT; Willemse PH; de Vries EG; Uges DR; Mulder NH
    Cancer Res; 1989 Aug; 49(16):4654-8. PubMed ID: 2545349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryopreserved autologous bone marrow transplantation in the treatment of selected pediatric malignancies: a preliminary report.
    Kaizer H; Leventhal BG; Wharam MD; Munoz LL; Elfenbein GJ; Tutschka PJ; Santos GW
    Transplant Proc; 1979 Mar; 11(1):208-11. PubMed ID: 377634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.
    Devereaux S; Linch DC; Gribben JG; McMillan A; Patterson K; Goldstone AH
    Bone Marrow Transplant; 1989 Jan; 4(1):49-54. PubMed ID: 2647187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer.
    Lazarus HM; Reed MD; Spitzer TR; Rabaa MS; Blumer JL
    Cancer Treat Rep; 1987; 71(7-8):689-95. PubMed ID: 3111687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
    Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L
    Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
    Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
    Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of human and murine hematopoietic precursor cells to 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Schein PS; Bull JM; Doukas D; Hoth D
    Cancer Res; 1978 Feb; 38(2):257-60. PubMed ID: 620400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.